Reveal Biosensors is developing physiologic sensing and control technologies for real-time management of oxygen exposure during oxygen supply transitions in neonatal, surgical anesthesia, and critical care medicine. Rapid increase in oxygen supply immediately following premature birth, currently guided by blood oxygen measurements, is associated with vital organ injuries and life-long disabilities. More generalized neurological injury in term and near-term newborns, currently referred to as hypoxic-ischemic encephalopathy (HIE), is also associated with rapid increase in oxygen supply during resuscitation. Pathologically-similar injuries later in life include post-anesthesia delirium (PAD) and cognitive decline in the elderly and ischemia/reperfusion injury (IRI) associated with therapy for ischemic stroke, heart attack, and organ transplant. These critical care therapies can now be updated and enhanced with closed-loop control of cellular oxygen delivery based on robust, full-scale, tissue-derived biometrics of oxygen utilization and cellular adaptation.

​

Our preliminary evidence offers new insight into the need to continuously detect and accommodate natural cellular adaptation during increases in oxygen supply to prevent oxygen therapy-related injuries. As an enhancement to existing physiologic monitoring, it appears that our new light absorption-based biometrics of cellular hypoxia and cellular hyperoxia will contribute to development of new methods of preventing injury, thereby reducing life-long burdens of disability.

 

Our business goal is to commercialize our patented IP defining this FDA-recognized new category of sensor technology and its novel methods of use through development of strategic IP licensing relationships with regulated medical device and healthcare platform providers.